A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

Inclusion Criteria: * Age between 18 and 70 years old * Patients with histologically confirmed unilateral invasive ductal carcinoma(according to WHO histologically type) * Tumor clinical staged as IIB-IIIB before neoadjuvant chemotherapy (according to the 7th AJCC edition). * After standard treatment (at least 6 cycles) of neoadjuvant chemotherapy (plan formulated by the attending doctor, including anthracycline and paclitaxel drugs combined with trastuzumab), assessed by the surgery, the original site for non - pCR (MP class 1-4) or lymph nodes are still positive for patients. * No gross or microscopic tumor residual after resection. * Patients with Her2 receptor positive (Specific definition: immunohistochemical detection of Her2 3+ or Her2 2 + but after FISH or CISH tested is positive). * No evidence of distant metastasis in the clinical or radiological aspects of preoperative. examination,that is M0. * Patients without peripheral neuropathy or I peripheral neurotoxicity. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1. * Patients recovered well after surgery, at least 1 weeks after the operation. * Adequate marrow: White blood cells count≥3000/μL,neutrophil count ≥1500/μL, hemoglobin ≥9g/dL and platelet count ≥75000/μL. * Normal liver function test: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) ≤ 1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤ 2.5×ULN, and bilirubin ≤ 1.5ULN. * Adequate renal function: Serum creatinine ≤ 1.5ULN. * Contraception during the treatment of child-bearing women. * Adequate cardiac function :Left ventricular ejection fraction (LVEF) \> 50%. * Patients must be informed of the investigational nature of this study and give written informed consent. * Patients without serious heart, lung, liver, kidney and other important organs disease history. * Patients have good compliance. Exclusion Criteria: * Patients with bilateral breast cancer or carcinoma in situ(DCIS/LCIS). * Metastasis of any part except axillary lymph nodes. * Clinical or imaging suspicion of the contralateral breast is malignant but not confirmed, requiring biopsy. * There have been malignant tumors (except for basal cell carcinoma and carcinoma in situ of cervix) in the last five years, including breast cancer. * Patients have been enrolled in other clinical trials. * Patients with severe systemic illnesses and/or uncontrolled infections are unable to join the study. * Patients with severe cardio-cerebrovascular disorders (e.g., unstable angina pectoris, chronic heart failure, uncontrollable hypertension \>160/100mmgh, myocardial infarction or cerebrovascular accident) in the first 6 months of randomization. * Pregnant lactating women (child-bearing women must be negative for pregnancy test within 14 days prior to first delivery, if positive, the pregnancy should be excluded by ultrasound.) * Child-bearing women who are unwilling to take effective contraceptive measures in the course of research. * Patients with mental illness, cognitive impairment, inability to understand test protocols and side effects, and those who fail to complete the trial programme and follow-up work (a systematic assessment is required before the trial). * Persons without personal freedom and independent civil capacity.